Clay B. Siegall
Clay B. Siegall's purchase track record
How the stock did after each of Clay B. Siegall's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/9/2026 | STTK | $250K | +52.2% | pending | — |
| 3/27/2026 | IMNM | $501K | +1.8% | +9.2% | +21.6% |
| 12/30/2025 | IMNM | $100K | +3.3% | +0.1% | +8.8% |
| 12/18/2025 | IMNM | $1.15M | +4.4% | -6.1% | +10.7% |
| 3/26/2025 | IMNM | $999K | +22.4% | +58.0% | +16.2% |
| 1/31/2025 | IMNM | $1.16M | -19.8% | -4.0% | +3.3% |
| 11/21/2024 | IMNM | $962K | +7.3% | -10.2% | -1.8% |
| 5/20/2024 | IMNM | $1.39M | +3.6% | -31.6% | +11.0% |
| 10/2/2023 | IMNM | $1000K | +34.3% | +169.6% | +22.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UBS initiates coverage on Shattuck Labs with $17 price target. UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.
Transaction History
| IMNM | ▲ Buy | Grant | 180,000 | $0 | 7/23/2026 | View on chart |
| STTK | ▲ Buy | Open Market | 62,500 | $250K | 6/9/2026 | View on chart |
| STTK | ▲ Buy | Grant | 128,054 | $139K | 5/22/2026 | View on chart |
| IMNM | ▲ Buy | Open Market | 25,450 | $501K | 3/27/2026 | View on chart |
| IMNM | ▲ Buy | Open Market | 4,729 | $100K | 12/30/2025 | View on chart |
| IMNM | ▲ Buy | Open Market | 7,278 | $149K | 12/19/2025 | View on chart |
| IMNM | ▼ Sell | Gift | 200,000 | $0 | 12/19/2025 | View on chart |
| IMNM | ▲ Buy | Open Market | 46,511 | $1000K | 12/18/2025 | View on chart |
| STTK | ▲ Buy | Grant | 128,054 | $111K | 8/25/2025 | View on chart |
| IMNM | ▲ Buy | Open Market | 137,100 | $999K | 3/26/2025 | View on chart |
| IMNM | ▲ Buy | Open Market | 150,000 | $1.2M | 1/31/2025 | View on chart |
| IMNM | ▲ Buy | Open Market | 33,943 | $332K | 11/22/2024 | View on chart |
| IMNM | ▲ Buy | Open Market | 66,057 | $630K | 11/21/2024 | View on chart |
| IMNM | ▲ Buy | Open Market | 20,434 | $282K | 5/21/2024 | View on chart |
| IMNM | ▲ Buy | Open Market | 79,566 | $1.1M | 5/20/2024 | View on chart |
| IMNM | ▲ Buy | Open Market | 169,204 | $1000K | 10/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.